These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Clinical application of (18)F-FDG PET/CT to staging and treatment effectiveness monitoring of nasopharyngeal carcinoma]. Wang GH; Lau EW; Shakher R; Binns DS; Hogg A; Drummond E; Hicks RJ Ai Zheng; 2007 Jun; 26(6):638-42. PubMed ID: 17562272 [TBL] [Abstract][Full Text] [Related]
23. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. Park JW; Jo MK; Lee HM BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371 [TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046 [TBL] [Abstract][Full Text] [Related]
25. (18)F-Fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of idiopathic retroperitoneal fibrosis associated with mediastinal fibrosis. Washino S; Hirai M; Matsuzaki A; Kobayashi Y Ann Nucl Med; 2010 Apr; 24(3):225-9. PubMed ID: 20112003 [TBL] [Abstract][Full Text] [Related]
26. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib]. Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858 [TBL] [Abstract][Full Text] [Related]
27. [¹⁸F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Bertagna F; Treglia G; Leccisotti L; Bosio G; Motta F; Giordano A; Giubbini R Jpn J Radiol; 2012 Jun; 30(5):415-21. PubMed ID: 22421932 [TBL] [Abstract][Full Text] [Related]
28. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases]. Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458 [TBL] [Abstract][Full Text] [Related]
29. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas]. Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637 [TBL] [Abstract][Full Text] [Related]
30. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer. van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729 [TBL] [Abstract][Full Text] [Related]
31. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology. El-Bawab H; Al-Sugair AA; Rafay M; Hajjar W; Mahdy M; Al-Kattan K Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120 [TBL] [Abstract][Full Text] [Related]
32. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
33. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. Du Y; Cullum I; Illidge TM; Ell PJ J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153 [TBL] [Abstract][Full Text] [Related]
34. Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis. Pipitone N; Versari A; Vaglio A; Salvarani C Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S72-8. PubMed ID: 21418782 [TBL] [Abstract][Full Text] [Related]
35. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer. Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451 [TBL] [Abstract][Full Text] [Related]
36. Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review. Grozdic Milojevic IT; Milojevic B; Sobic-Saranovic DP; Artiko VM Rheumatol Int; 2018 Feb; 38(2):179-187. PubMed ID: 28840309 [TBL] [Abstract][Full Text] [Related]
37. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma. Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950 [TBL] [Abstract][Full Text] [Related]
38. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Thrall MM; DeLoia JA; Gallion H; Avril N Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284 [TBL] [Abstract][Full Text] [Related]
39. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105 [TBL] [Abstract][Full Text] [Related]
40. F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Balink H; Collins J; Bruyn GA; Gemmel F Clin Nucl Med; 2009 Dec; 34(12):862-8. PubMed ID: 20139818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]